When it comes to using technology along with healthcare services in the 21st century, we tend to look at rather broad based tools. We talk about call centers that have been opened to explain to people what new insurance regulations mean. We often talk about using video conferencing tools in order to help doctors see patients from afar. And every so often we actually talk about how technology is helping us battle specific diseases, but these approaches seem to get lost in the crowd.
The world is seeing a burgeoning new epidemic on the horizon when it comes to diabetes. The number of people who are showing signs of developing the disorder is currently three times as high as those who have actually been diagnosed. Because of this potential spike, more pharmaceutical companies are being called upon to come up with more effective type 2 diabetes drugs.
Frost & Sullivan has just released a new report which indicates that those companies are attempting to meet the demand. The new report says that 15 new drugs that are geared towards treating type 2 diabetes are in the latter stages of development. Frost & Sullivan’s Life Sciences Global Program Director, Jennifer Lazar Brice talked about the report her company put out in a recent release.
“The type 2 diabetes market continually advances, primarily due to the dominance of obesity,” Lazar Brice said. “Current studies of this increasingly competitive market are limited in their approach. Seeing this missed opportunity, we began addressing such markets in a new way. Our repositioned Life Sciences program includes therapeutic product and pipeline analyses and services focused on our clients’ proactive competitive intelligence goals. Among the many trends we see coming, the pharma industry will address the ubiquity of diabetes by a steady stream of new product launches over the next six years.”
These new treatment options are meeting patient needs that had previously been unmet. Because these new drugs are hitting the market so quickly, and serve such needs, regulatory authorities are approving drugs quicker. Frost & Sullivan has warned that this approach could actually lead to regulatory failures. With so many type 2 drugs hitting the market over the next few years, the success and potential side effects will need to be monitored closely.
Edited by
Alisen Downey
